Fadrozole

Fadrozole
Systematic (IUPAC) name
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
Clinical data
  • ℞ (Prescription only)
Oral
Identifiers
102676-31-3 Yes
None
PubChem CID 59693
ChemSpider 53850 
UNII H3988M64PU 
KEGG D02451 Yes
ChEMBL CHEMBL9298 
Chemical data
Formula C14H13N3
223.27 g/mol
  (what is this?)  (verify)

Fadrozole (INN, marketed as Afema by Novartis) is an aromatase inhibitor[1] that has been introduced in Japan for the treatment of breast cancer.

It is selective.[2]

References

  1. ↑ Raats JI, Falkson G, Falkson HC (January 1992). "A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer". J. Clin. Oncol. 10 (1): 111–6. PMID 1530798.
  2. ↑ Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A (February 1991). "Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease". J. Med. Chem. 34 (2): 725–36. doi:10.1021/jm00106a038. PMID 1825337.

See also